TRYP
THERAPEUTICS

CORPORATE PRESENTATION

Fall 2021

CSE: TRYP
OTCQB: TRYPF

Disclaimer

The information contained in this presentation (the "Presentation") has been prepared by Tryp Therapeutics Inc. ("Tryp" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in Tryp. This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Tryp. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Tryp, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this Presentation, or for the accuracy, completeness, or usefulness of any information disclosed in this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Tryp. By their nature, forward looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward looking statements. In addition, the forward looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward looking statements will not prove to be accurate, that Tryp's assumptions may not be correct and that actual results may differ materially from such forward looking statements. Accordingly, readers should not place undue reliance on the forward looking statements. Generally, forward looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Tryp's business strategy (including its business model and mission); the use and benefits of Tryp's products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Tryp; the potential impact of the COVID-19 pandemic on Tryp's business or operations; and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance, expected regulatory filings, review and approval dates, and start-up timelines and schedules, and statements related to the continued overall advancement of Tryp's business. These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward looking statements contained in this Presentation are made as of the date hereof or the dates specifically referenced in this Presentation, where applicable. Except as required by law, Tryp undertakes no obligation to update publicly or to revise any forward looking statements that are contained or incorporated in this Presentation. All forward looking statements contained in this Presentation are expressly qualified by this cautionary statement.

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information. Some numbers in this Presentation may not be exact or add consistently due to rounding.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

TRYP THERAPEUTICS IS LEADING THE NEXT WAVE OF PSYCHEDELIC DRUG DEVELOPMENT BEYOND MENTAL HEALTH WITH OUR FOCUS ON CHRONIC PAIN AND OTHER INDICATIONS



A NEW ERA FOR PSILOCYBIN

We are revolutionizing what psilocybin-based treatments can do with leading-edge therapies for chronic pain and other indications.



UNLEASHING THE FULL POTENTIAL OF PSILOCYBIN

Tryp differs from other psychedelic drug development companies in four important ways:

01

Unique, highly valuable indications

While mental health indications such as depression, anxiety, and addiction are being pursued by multiple companies, Tryp is breaking new ground in chronic pain and eating disorders. Taken together, the commercial potential of our development programs exceeds $12 billion in peak annual sales.



UNLEASHING THE FULL POTENTIAL OF PSILOCYBIN

Tryp differs from other psychedelic drug development companies in four important ways:

02

A proprietary formulation and delivery method

Our psilocybin-based drug product, TRP-8803, features a proprietary formulation and novel method of administration to improve the patient experience. We have filed a provisional patent to protect the unique features of TRP-8803—a foundational piece of intellectual property for Tryp.

UNLEASHING THE FULL POTENTIAL OF PSILOCYBIN

Tryp differs from other psychedelic drug development companies in four important ways:

03

Exclusive manufacturing

We have secured an exclusive supply of our psilocybin-based active ingredients and drug products, with sufficient quantities of material to support clinical trials and ultimate commercialization—a rare capability among psychedelic drug development companies.



UNLEASHING THE FULL POTENTIAL OF PSILOCYBIN

Tryp differs from other psychedelic drug development companies in four important ways:

04

The right people at the right time

We have assembled foremost experts in drug development and psychedelics within Tryp while partnering with academic collaborators with unrivaled leadership within their respective indications. Our Scientific Advisor Board is chaired by Robin Carhart-Harris, PhD, a preeminent, global expert on the clinical application of psychedelics.

WE ARE DRIVEN BY PATIENT OUTCOMES

Tryp focuses on areas of unmet medical need where other treatments have fallen short.

Millions of people suffer from health conditions, like chronic pain, for which few or no effective treatment options currently exist.

Each one of these conditions is a humanitarian need—and an unaddressed market opportunity.

Our pharmaceutical focus on psilocybin has the potential to transform the treatment of chronic pain and other indications, and relieve the suffering of millions of patients.

Current state

+ Daily medications
+ Hard-to-live-with side effects
+ **Treating the symptoms**

Our vision for the future

+ Treatment given once or twice a year
+ Patient-friendly drug administered with psychotherapy
+ **Treating the disease**

MILLIONS OF PATIENTS ARE SUFFERING FROM CHRONIC PAIN

Fibromyalgia

Existing treatments have limited efficacy and significant side effects for the 4 million individuals in the US who have been diagnosed with fibromyalgia.

Fewer than 10% of patients adhere to approved treatments after one year.

Nearly 30% of patients take opioids despite the lack of evidence for efficacy and the risk of addiction and/or overdose.

Phantom Limb Pain

More than 1 million people have been diagnosed with phantom limb pain in the United States.

Existing treatment methods—such as general pain medication, mirror therapy and acupuncture—are ineffective for many patients.

Because this pain is neurological, it is a prime target for treatment with psilocybin.

CRPS

CRPS results from misfiring of pain signals within the brain after an injury, surgery, stroke or heart attack.

We estimate that nearly 100,000 people have been diagnosed with CRPS in the United States.

Current treatments are ineffective, leaving physicians with few options for suffering patients.

https://pubmed.ncbi.nlm.nih.gov/26755658/ | https://www.jrheum.org/content/early/2017/07/26/jrheum.170098
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240431 | https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.445.2671&rep=rep1&type=pdf

LIVING WITH AN OVEREATING DISORDER CAN FEEL LIKE THERE IS NO END IN SIGHT

Binge eating disorder

- BED is characterized by recurring episodes of eating large quantities of food and feeling unable to stop.
- Nearly 30% of people seeking weight loss treatments show signs of BED.
- Up to 3.5% of females and 2.0% of males will develop BED at some point in their lives.



Hypothalamic Obesity

- Hypothalamic obesity, a rare disease, is caused by damage to the hypothalamus, which controls hunger.
- The damage is often caused by surgical removal of a brain tumor.
- This condition can dominate patients' day-to-day lives, and with no FDA-approved therapies available for the condition, patients have few options.

"We're very excited for the potential of Tryp's treatment. The potential impact on patients' lives is that it would be life changing for them."

— **Jennifer Miller,**
Professor, University of Florida

https://www.nationaleatingdisorders.org/statistics-research-eating-disorders

OUR SOLUTIONS:

TRP-8802 (ORAL SYNTHETIC PSILOCYBIN)

TRP-8802 is a non-proprietary 25 mg oral capsule of synthetic psilocybin sourced from Usona Institute.

PROGRAM	INDICATION	EVALUTION	PHASE	
			2A	2B
TRP-8802 ↓	FIBROMYALGIA			
	PHANTOM LIMB PAIN			
	CRPS			
	BINGE EATING DISORDER			
	HYPOTHALAMIC OBESITY			

CURRENT
NEXT 18 MONTHS

Using TRP-8802 for our Phase 2a studies allows us to quickly initiate our clinical trials as we determine the effectiveness of psilocybin for our target indications.

OUR SOLUTIONS:

TRP-8803 (PROPRIETARY, PSILOCYBIN-BASED FORMULATION)

TRP-8803 is a proprietary psilocybin-based drug product manufactured exclusively for Tryp by Curia and Alcami.



The novel formulation and route of administration are expected to improve the patient experience and to enhance patient safety.

We expect TRP-8803 to be used for Tryp's Phase 2b clinical trials and beyond.

Tryp expects to use multiple data sets to support the use of TRP-8803 in Phase 2b studies and eventual commercialization, including:

- Preclinical data for TRP-8803
- Clinical pharmacology data for TRP-8803
- Phase 2a data for TRP-8802

Preclinical and Phase 1 data for TRP-8803 is being generated in partnership with the University of Michigan and Calvert Labs.

Additional details of TRP-8803 will be disclosed in 1Q 2022 once additional intellectual property filings for the product have been submitted.

A CLOSER LOOK: PHASE 2A CLINICAL TRIAL FOR FIBROMYALGIA

	Product	No. of Patients	Collaborator	Design	Data Read Out	Next Steps
Fibromyalgia	TRP-8802	20	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 4Q 2021 and begin enrollment in 1Q 2022

A CLOSER LOOK: PHASE 2A CLINICAL TRIAL FOR PHANTOM LIMB PAIN

	Product	No. of Patients	Collaborator	Design	Data Read Out	Next Steps
Fibromyalgia	TRP-8802	20	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 4Q 2021 and begin enrollment in 1Q 2022
Phantom Limb Pain	TRP-8802	50	TBA in Q4 2021	Placebo controlled with psychotherapy	Interim data expected in 2022	IND has been submitted; begin enrollment in 4Q 2021

A CLOSER LOOK: PHASE 2A CLINICAL TRIAL FOR CRPS

	Product	No. of Patients	Collaborator	Design	Data Read Out	Next Steps
Fibromyalgia	TRP-8802	20	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 4Q 2021 and begin enrollment in 1Q 2022
Phantom Limb Pain	TRP-8802	50	TBA in Q4 2021	Placebo controlled with psychotherapy	Interim data expected in 2022	IND has been submitted; begin enrollment in 4Q 2021
CRPS	TRP-8802	10	TBA in Q4 2021	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 1Q 2022 and begin enrollment in 2Q 2022

WE ARE ON THE CUSP OF INITIATING MULTIPLE PHASE 2A CLINICAL TRIALS IN CHRONIC PAIN

	Product	No. of Patients	Collaborator	Design	Data Read Out	Next Steps
Fibromyalgia	TRP-8802	20	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 4Q 2021 and begin enrollment in 1Q 2022
Phantom Limb Pain	TRP-8802	50	TBA in Q4 2021	Placebo controlled with psychotherapy	Interim data expected in 2022	IND has been submitted; begin enrollment in 4Q 2021
CRPS	TRP-8802	10	TBA in Q4 2021	Open label with psychotherapy	Interim data expected in 2022	Submit IND in 1Q 2022 and begin enrollment in 2Q 2022



A CLOSER LOOK: PHASE 2A CLINICAL TRIAL FOR EATING DISORDERS

	Product	No. of Patients	Collaborator	Indications	Design	Data Read Out	Next Steps
Eating Disorders	TRP-8802	10	UF UNIVERSITY of FLORIDA	Binge eating disorder, hypothalamic obesity, Prader-Willi syndrome	Open label with psychotherapy	Interim data expected in 2022	IND submitted; begin enrollment in 4Q 2021

WE ARE ON THE CUSP OF INITIATING OUR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS

	Product	No. of Patients	Collaborator	Indications	Design	Data Read Out	Next Steps
Eating Disorders	TRP-8802	10	UF UNIVERSITY of FLORIDA	Binge eating disorder, hypothalamic obesity, Prader-Willi syndrome	Open label with psychotherapy	Interim data expected in 2022	IND submitted; begin enrollment in 4Q 2021



EXCLUSIVE MANUFACTURING AND SUPPLY OF SYNTHETIC PSILOCYBIN FOR OUR DRUG PRODUCTS

Tryp has secured an exclusive supply of our psilocybin-based active ingredients and drug products, with sufficient quantities of material to support clinical trials and ultimate commercialization—a rare capability among psychedelic drug development companies.

Our Partners

Curia (formerly AMRI) manufactures our Active Pharmaceutical Ingredient (API) through a proprietary process.

Alcami manufactures and develops analytical methods for our final drug products.

Working at scale

We've already completed engineering batches for our API, and expect to have more than 2 kg of cGMP material in 2021.

We are already scaled for full commercial quantities.

INTELLECTUAL PROPERTY

- Our intellectual property, including patent applications and trade secrets, is based on novel methods for the manufacturing, formulating, dosing, and administering of psychedelic compounds resulting in material benefits across multiple indications
- Tryp most recently filed a provisional patent in March 2021 (US 63/161,070) describing innovative techniques resulting in a potential reduction in the time spent by patients in the dissociative state
- We have retained Morrison & Foerster to prosecute our patent applications

MORRISON FOERSTER

THE RIGHT PEOPLE AT THE RIGHT TIME

Greg McKee
Chairman and CEO

25+ years experience as CEO leading publicly traded biopharma companies and other organizations

Jim Gilligan, Ph.D.
President and CSO

35+ years of experience including R&D, clinical development, regulatory affairs, and manufacturing

Luke Hayes
Chief Financial Officer

20+ years of life science experience in finance, venture capital, business development, and technology transfer



Tom D'Orazio
Chief Operating Officer

Extensive experience developing and commercializing vaccines, drugs, radiopharmaceuticals, and biologics

Peter Guzzo, Ph.D.
VP, Drug Development

25+ years of experience developing innovative therapeutics for diseases with limited treatment options

Larry Norder
VP, Manufacturing

30+ years of experience in the pharmaceutical industry including manufacturing and drug delivery

Joy Willis
Director, Investor Relations

Prior experience as an Analyst at Solebury Trout, a leading investor relations firm for life science companies

A WORLD-CLASS ROSTER OF SCIENTIFIC ADVISORS



Robin Carhart-Harris, Ph.D. (SAB Chairman)

Global expert on use of psychedelics for medical indications

UCSF Imperial College London



Rachel Wervick, Ph.D.

Leading researcher in genetic development, including eating disorders

UNIVERSITY OF ALBERTA

Daniel Clauw, M.D.

World-renowned expert on fibromyalgia and nociplastic pain

UNIVERSITY OF MICHIGAN

Joel Castellanos, M.D.

Leading chronic pain researcher and physician

UC San Diego



William Schmidt, Ph.D.

Expert in drug development for pain indications

UCSF

Derek Ott, M.D.

30+ years of experience in the pharmaceutical industry including manufacturing and drug delivery

UCLA

“I am impressed with the breadth and depth of Tryp’s experience and am pleased to complement this team with my own psychedelic-specific expertise.”

— **Robin Carhart-Harris, Ph.D.**
Chairman
Scientific Advisory Board

THE HIGH PREVALENCE OF OUR TARGET INDICATIONS CREATES A COMPELLING MARKET OPPORTUNITY

Tryp is pursuing chronic pain and other indications to address the significant needs of patients.

Because of the relatively high prevalence of these diseases, the market opportunity for the successful development and commercialization of our treatments is more than **$12 billion** in annual sales.

Diagnosed Prevalence in the U.S.



Peak Annual Worldwide Sales Potential for Tryp



Figures based on internal analysis by Tryp Therapeutics. Details of prevalence assumptions available upon request.

CLEAR DIFFERENTIATION AMONG PSYCHEDELIC DRUG DEVELOPMENT COMPANIES

Tryp is one of just a handful of psychedelic drug development companies that will be conducting Phase 2 clinical trials in 2021.

While mental health indications such as depression, anxiety, and addiction are crowded by multiple companies, Tryp Therapeutics is breaking new ground in chronic pain and other indications.

Competitive Landscape: Psychedelic Drug Development Companies



CAPITALIZATION AND MARKET INFORMATION

	TRYP THERAPEUTICS	ATAI	COMPASS	MINDMED	CYBIN	SEELOS
EXCHANGE/SYMBOL	**CSE:TRYP**	NASDAQ:ATAI	NASDAQ:CMPS	NASDAQ:MNMD	NYSEA:CYBN	NASDAQ:SEEL
MARKET CAPITALIZATION	**$33M**	**$3.1B**	**$1.7B**	**$1.2B**	**$455M**	**$304M**

Share price as of 9/24/21	**C$0.49**
Market cap as of 9/24/21	**C$33.0 million**

Analyst Coverage: LADENBURG THALMANN ESTABLISHED 1876 **MICHAEL HIGGINS**

CAPITAL STRUCTURE

ISSUED AND OUTSTANDING	66,668,759
WARRANTS	9,361,019
OPTIONS & COMP UNITS	14,864,680
FULLY DILUTED	**90,894,458**

Any opinions, estimates or forecasts regarding Tryp Therapeutics Inc.'s performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of Tryp Therapeutics Inc. or its management. Tryp Therapeutics Inc. does not by its reference imply its endorsement of or concurrence with such information, conclusions or recommendations.

FORECASTED NEWSFLOW

4Q 21

- IND filing for Phase 2a study for fibromyalgia
- Announcement of additional academic collaborations for phantom limb pain and CRPS
- Enrollment of first patient in Phase 2a study for eating disorders
- Enrollment of first patient Phase 2a study for phantom limb pain
- Manufacturing of cGMP Active Pharmaceutical Ingredient (API)
- Additional intellectual property filings

1Q 22

- IND filing for CRPS
- Enrollment of first patient in Phase 2a study for fibromyalgia
- Disclosure of details on TRP-8803
- Additional intellectual property filings

2Q 22

- Enrollment of first patient in Phase 2a study for CRPS
- Interim data read out for Phase 2a study in eating disorders
- Completion of preclinical studies for TRP-8803
- Additional intellectual property filings

3Q 22

- Interim data read out for Phase 2a study in fibromyalgia
- Completion of clinical pharmacology study for TRP-8803
- Additional intellectual property filings

LEADING THE NEXT WAVE OF PSYCHEDELIC DRUG DEVELOPMENT

Tryp's differentiated approach to psychedelic drug development has the potential to deliver urgently needed treatments to millions of patients suffering from chronic pain and other diseases while creating significant opportunity for investors.

We are well positioned for success:

1. **Unique, highly valuable indications**
Our imminent Phase 2a clinical trials represent the first time that any type of psychedelic has been evaluated for the respective indications in a Phase 2 study. Fibromyalgia, phantom limb pain, CRPS, binge eating disorder, and hypothalamic obesity represent more than $12 billion of potential peak annual sales upon successful commercialization.

2. **A proprietary formulation and delivery method**
TRP-8803, our novel formulation, is poised to disrupt the dosing and administration of psilocybin-based drug products, with the aim of creating a better patient experience.

3. **Exclusive manufacturing**
Our exclusive supply of synthetic psilocybin provides a rare capability among psychedelic drug development companies with ample material to meet all of our clinical trial and commercialization needs.

4. **The right people at the right time**
We are constantly expanding our roster of both internal and collaborative experts to drive world-class outcomes.

TRYP
THERAPEUTICS

tryptherapeutics.com

For questions, please contact:
investors@tryptherapeutics.com

@tryptherapeutic

CSE: TRYP
OTCQB: TRYPF